Results

Most recent

AMD-Neovascular

1–10 of 184 results for AMD-Neovascular

Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel:PDS
Robert A. Mittra, MD, FASRS
Dante Joseph Pieramici, MD
Aleksandra V. Rachitskaya, MD, FASRS
Margaret A. Chang, MD, MS
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2024
Charlson Comorbidity Index As a Predictive Tool in Patients With Exudative Age-Related Macular Degeneration in Delay of Care
Vivienne S. Hau, MD, PhD
Annual Meeting Talks
2024
Intravitreal Therapeutics Utilization in 2023
Anton M Kolomeyer, MD, PhD
Annual Meeting Talks
2024
Assessment on Pre-to-Post Switching Efficacy and Safety of SB15 (Proposed Aflibercept Biosimilar): Post Hoc Analysis of a Phase 3 Clinical Trial
Srinivas Reddy Sadda, MD
Annual Meeting Talks
2024
Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO
Nikhil K Bommakanti, MD
Annual Meeting Talks
2024
Pigment Epithelial Detachment Outcomes With Faricimab vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Aude Ambresin, MD, PD
Annual Meeting Talks
2024
Factors Associated With the Development of Exudation in Treatment-Naïve Eyes With Nonexudative Macular Neovascularization
HAN JOO CHO, MD
Annual Meeting Talks
2024
Association Between Provider Anti-VEGF Injection Rates and Visual Outcome In Eyes With Neovascular Age-Related Macular Degeneration
Michael M. Lai, MD, PhD
Annual Meeting Talks
2024
Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024